FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely to a solid composition for oral administration for the treatment of diabetes mellitus and/or obesity, containing the effective amount of semaglutide or its pharmaceutically acceptable salt or solvate, and the effective amount of dapagliflozin or its pharmaceutically acceptable salt or solvate. The composition preferably additionally contains a sodium absorption enhancer N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).
EFFECT: invention provides compositions with improved penetration of GLP-1 peptides through cell membrane, which is necessary for increasing their bioavailability in the oral administration.
7 cl, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| ACYLATED GLUCAGON ANALOGUE, USE THEREOF AND METHODS OF PRODUCING | 2016 |
|
RU2735762C2 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| ACYLATED DOUBLE AGONISTS OF GLP-1/GLP-2 | 2017 |
|
RU2753193C2 |
